4.7 Article

Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms

Journal

ALZHEIMERS & DEMENTIA
Volume 14, Issue 2, Pages 205-214

Publisher

WILEY
DOI: 10.1016/j.jalz.2017.08.013

Keywords

Polygenic risk score; Sporadic late-onset Alzheimer's disease; Early-onset Alzheimer's disease; Early-onset autosomal dominant; Late-onset Alzheimer's disease; Dominantly inherited Alzheimer network; APOE; APP; PSEN1; PSEN2; Genetic architecture; Area under the curve; Genetic risk factor; Disease modifier; Age at onset; Cerebrospinal fluid; A beta; Tau

Funding

  1. National Institutes of Health [R01-AG044546, P01-AG003991, RF1AG053303, R01-AG035083, R01-NS085419]
  2. Alzheimer's Association [NIRG-11-200110]
  3. American Federation for Aging Research
  4. BrightFocus Foundation Alzheimer's Disease Research grant [A2013359S]
  5. NIH [P50 AG05681, P01 AG03991, P01 AG026276]
  6. Dominantly Inherited Alzheimer Network (DIAN) - National Institute on Aging (NIA) [U19AG032438, P50 AG-16570, P50 AG-005142]
  7. German Center for Neurodegenerative Diseases (DZNE)
  8. NIHR Queen Square Dementia Biomedical Research Unit
  9. MRC Dementias Platform UK [MR/L023784/1, MR/009076/1]
  10. DIAN-TU Pharma Consortium, (DIAN-TU Pharma Consortium)
  11. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  12. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  13. National Institute on Aging
  14. National Institute of Biomedical Imaging and Bioengineering
  15. AbbVie
  16. Alzheimer's Association
  17. Alzheimer's Drug Discovery Foundation
  18. Araclon Biotech
  19. BioClinica, Inc.
  20. Biogen
  21. Bristol-Myers Squibb Company
  22. CereSpir, Inc.
  23. Cogstate
  24. Eisai Inc.
  25. Elan Pharmaceuticals, Inc.
  26. Eli Lilly and Company
  27. EuroImmun
  28. F. Hoffmann-La Roche Ltd.
  29. Genentech, Inc.
  30. Fujirebio
  31. GE Healthcare
  32. IXICO Ltd.
  33. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  34. Johnson & Johnson Pharmaceutical Research & Development LLC.
  35. Lumosity
  36. Lundbeck
  37. Merck Co., Inc.
  38. Meso Scale Diagnostics, LLC.
  39. NeuroRx Research
  40. Neurotrack Technologies
  41. Novartis Pharmaceuticals Corporation
  42. Pfizer Inc.
  43. Piramal Imaging
  44. Servier
  45. Takeda Pharmaceutical Company
  46. Transition Therapeutics
  47. Canadian Institutes of Health Research
  48. NCI Cancer Center [P30 CA91842]
  49. ICTS/CTSA from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [UL1TR000448]
  50. NIH Roadmap for Medical Research

Ask authors/readers for more resources

Objective: To determine whether the extent of overlap of the genetic architecture among the sporadic late-onset Alzheimer's Disease (sLOAD), familial late-onset AD (fLOAD), sporadic earlyonset AD (sEOAD), and autosomal dominant early-onset AD (eADAD). Methods: Polygenic risk scores (PRSs) were constructed using previously identified 21 genome-wide significant loci for LOAD risk. Results: We found that there is an overlap in the genetic architecture among sEOAD, fLOAD, and sLOAD. The highest association of the PRS and risk (odds ratio [OR] = 2.27; P = 1.29 X 10(-7)) was observed in sEOAD, followed by fLOAD (OR = 1.75; P = 1.12 X 10(-7)) and sLOAD (OR = 1.40; P = 1.21 X 10(-3)). The PRS was associated with cerebrospinal fluid ptau(181)-A beta(42) on eADAD (P = 4.36 X 10(-2)). Conclusion: Our analysis confirms that the genetic factors identified for LOAD modulate risk in sLOAD and fLOAD and also sEOAD cohorts. Specifically, our results suggest that the burden of these risk variants is associated with familial clustering and earlier onset of AD. Although these variants are not associated with risk in the eADAD, they may be modulating age at onset. (C) 2017 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available